ScholarIQanswers from OpenAlex
Daiichi Sankyo (Germany)
InstitutionResearch output, impact & collaborations
Daiichi Sankyo (Germany) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Daiichi Sankyo (Germany)?
ScholarIQrecord summary
Daiichi Sankyo (Germany) is a research organisation in Munich, DE. OpenAlex records 3,191 works and 251,610 citations for it. 951 researchers list it as their most recent affiliation.
How many works does Daiichi Sankyo (Germany) have?
ScholarIQindexed works
Daiichi Sankyo (Germany) has 3,191 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Daiichi Sankyo (Germany) have?
ScholarIQcitation count
Daiichi Sankyo (Germany) has 251,610 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Daiichi Sankyo (Germany)?
ScholarIQresearcher count
Daiichi Sankyo (Germany) has 951 researchers in the ScholarIQ index.
What is the average h-index at Daiichi Sankyo (Germany)?
ScholarIQavg h-index
Daiichi Sankyo (Germany) has an average h-index of 36 in OpenAlex.
What is the ROR of Daiichi Sankyo (Germany)?
ScholarIQror
The ROR for Daiichi Sankyo (Germany) is on the source record.
What is the OpenAlex record for Daiichi Sankyo (Germany)?
ScholarIQopenalex
The OpenAlex for Daiichi Sankyo (Germany) is on the source record.
What is the Wikidata of Daiichi Sankyo (Germany)?
ScholarIQwikidata
The Wikidata for Daiichi Sankyo (Germany) is on the source record.
Who are the most-cited researchers behind Daiichi Sankyo (Germany)?
ScholarIQtop researchers by citations
What are the most-cited papers on Daiichi Sankyo (Germany)?
ScholarIQmost cited works
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D. Lewis, P. Combemale, R. M. Herd, Ragini R. Kudchadkar, Uwe Trefzer, Sven Gogov, Céline Pallaud, Tingting Yi, Manisha Mone, Martin Kaatz, Carmen Loquai, Alexander Stratigos, H. J. Schulze, Ruth Plummer, Anne Lynn S. Chang, Frank Cornélis, John T. Lear, Dalila Sellami, Reinhard Dummer
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
Reinhard Dummer, Alexander D. Guminksi, Ralf Gutzmer, John T. Lear, Karl D. Lewis, Anne Lynn S. Chang, P. Combemale, Luc Dirix, Martin Kaatz, Ragini R. Kudchadkar, Carmen Loquai, Ruth Plummer, H.‐J. Schulze, Alexander Stratigos, Uwe Trefzer, Nicholas Squittieri, Michael R. Migden
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
John T. Lear, Michael R. Migden, Karl D. Lewis, Anne Lynn S. Chang, Alexander Guminski, Ralf Gutzmer, Luc Dirix, P. Combemale, Alexander Stratigos, Ruth Plummer, Henry Castro, Tingting Yi, Manisha Mone, J ZHOU, Uwe Trefzer, Martin Kaatz, Carmen Loquai, Ragini R. Kudchadkar, Dalila Sellami, Reinhard Dummer
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth
Siyuan Xia, Ruiting Lin, Lingtao Jin, Liang Zhao, Hee‐Bum Kang, Yaozhu Pan, Shuangping Liu, Guoqing Qian, Zhiyu Qian, Evmorfia Konstantakou, Baotong Zhang, Jin‐Tang Dong, Young Rock Chung, Omar Abdel‐Wahab, Taha Merghoub, Lu Zhou, Ragini R. Kudchadkar, David H. Lawson, H. Jean Khoury, Fadlo R. Khuri, Lawrence Boise, Sagar Lonial, Benjamin H. Lee, Brian P. Pollack, Jack L. Arbiser, Jun Fan, Qun‐Ying Lei, Jing Chen
How much of the research on Daiichi Sankyo (Germany) is open access?
ScholarIQopen access share
75%OPEN ACCESS